Rigel Pharmaceuticals
RIGL
110 hedge funds and large institutions have $300M invested in Rigel Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 15 closing their positions.
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
32% more capital invested
Capital invested by funds: $227M → $300M (+$73.5M)
17% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 30
10% more funds holding
Funds holding: 100 → 110 (+10)
52% less call options, than puts
Call options by funds: $579K | Put options by funds: $1.19M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$15M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.56M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.88M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$1.85M |
| 5 |
BC
Broadfin Capital
New York
|
+$1.78M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$19.1M |
| 2 |
VAM
Visium Asset Management
New York
|
-$5.03M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.81M |
| 4 |
Millennium Management
New York
|
-$3.63M |
| 5 |
Renaissance Technologies
New York
|
-$3.35M |
RIGL Hedge Fund Activity: Q1 2014 in Review
110 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2014, worth a combined $300M — up 32% from $227M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RIGL positions and 15 closed out — a net gain of 11 holders — while 35 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $15M. The largest seller was BVF Inc, cutting an estimated $19.1M.
- 110 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2014, up from 100 in Q4 2013.
- Funds reported $300M of Rigel Pharmaceuticals stock for Q1 2014, up 32% quarter-over-quarter.
- 26 funds opened new Rigel Pharmaceuticals positions in Q1 2014 and 15 closed out, a net change of +11 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $15M added.
- The largest Rigel Pharmaceuticals seller in Q1 2014 was BVF Inc, an estimated $19.1M sold.
Based on aggregated 13F filings for Q1 2014.